Halozyme Therapeutics Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 204.5% | 40.9% | 36.5% |
| FY2022 | 119.0% | 12.2% | 11.0% |
| FY2023 | 336.0% | 17.8% | 16.2% |
| FY2024 | 122.1% | 23.8% | 21.5% |
| FY2025 | 649.2% | 14.5% | 12.5% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 204.5% | 40.9% | 36.5% |
| FY2022 | 119.0% | 12.2% | 11.0% |
| FY2023 | 336.0% | 17.8% | 16.2% |
| FY2024 | 122.1% | 23.8% | 21.5% |
| FY2025 | 649.2% | 14.5% | 12.5% |